Prognostic factors after isolated ipsilateral local and regional recurrence in HER2-negative luminal breast cancer: a multi-center retrospective study

被引：0
|
作者：
Yong Hwa Eom
Chang IK Yoon
Young Joon Kang
Ye Won Jeon
机构：
[1] Eunpyeong St. Mary’s Hospital,Division of Breast Surgery, Department of Surgery
[2] College of Medicine,Division of Breast Surgery, Department of Surgery
[3] The Catholic University of Korea,Division of Breast Surgery, Department of Surgery
[4] Seoul St. Mary’s Hospital,Division of Breast Surgery, Department of Surgery, St. Vincent’s Hospital, College of Medicine
[5] College of Medicine,undefined
[6] The Catholic University of Korea,undefined
[7] Incheon St. Mary’s Hospital,undefined
[8] College of Medicine,undefined
[9] The Catholic University of Korea,undefined
[10] The Catholic University of Korea,undefined
来源：
World Journal of Surgical Oncology | / 21卷
关键词：
Breast cancer; Ipsilateral; Local recurrence; Luminal; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Prognostic Factors for Long-Term Eribulin Response in a Cohort of Patients With HER2-Negative Metastatic Breast Cancer
    El Kaddissi, Antoine
    Vernerey, Dewi
    Falcoz, Antoine
    Mansi, Laura
    Bazan, Fernando
    Chaigneau, Loic
    Dobi, Erion
    Goujon, Morgan
    Meneveau, Nathalie
    Paillard, Marie-Justine
    Selmani, Zohair
    Viot, Julien
    Molimard, Chloe
    Monnien, Franck
    Woronoff, Anne-Sophie
    Curtit, Elsa
    Borg, Christophe
    Meynard, Guillaume
    CLINICAL BREAST CANCER, 2024, 24 (07)
  • [32] Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study
    Jiang, Mingxia
    Shao, Bin
    Wan, Donggui
    Liu, Jiaxuan
    He, Maiyue
    Chai, Yue
    Sang, Die
    Wang, Jiayu
    Ma, Fei
    Fan, Ying
    Yuan, Peng
    Xu, Binghe
    Li, Qiao
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [33] Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis
    De Angelis, Carmine
    Di Maio, Massimo
    Crispo, Anna
    Giuliano, Mario
    Schettini, Francesco
    Bonotto, Marta
    Gerratana, Lorenzo
    Iacono, Donatella
    Cinausero, Marika
    Riccardi, Ferdinando
    Ciancia, Giuseppe
    De Laurentiis, Michelino
    Puglisi, Fabio
    De Placido, Sabino
    Arpino, Grazia
    ONCOTARGET, 2017, 8 (68) : 112816 - 112824
  • [34] Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using FDG PET in luminal. HER2-negative breast cancer
    Humbert, Olivier
    Berriolo-Riedinger, Alina
    Cochet, Alexandre
    Gauthier, Melanie
    Charon-Barra, Celine
    Desmoulins, Isabelle
    Guiu, Severine
    Toubeau, Michel
    Dygai-Cochet, Inna
    Coutant, Charles
    Fumoleau, Pierre
    Brunotte, Francois
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer
    Hiroko Yamashita
    Akiko Ogiya
    Tadahiko Shien
    Yoshiya Horimoto
    Norikazu Masuda
    Touko Inao
    Tomofumi Osako
    Masato Takahashi
    Yumi Endo
    Mitsuchika Hosoda
    Naoko Ishida
    Rie Horii
    Kieko Yamazaki
    Yuichiro Miyoshi
    Hiroyuki Yasojima
    Nobumoto Tomioka
    Breast Cancer, 2016, 23 : 830 - 843
  • [36] Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer
    Yamashita, Hiroko
    Ogiya, Akiko
    Shien, Tadahiko
    Horimoto, Yoshiya
    Masuda, Norikazu
    Inao, Touko
    Osako, Tomofumi
    Takahashi, Masato
    Endo, Yumi
    Hosoda, Mitsuchika
    Ishida, Naoko
    Horii, Rie
    Yamazaki, Kieko
    Miyoshi, Yuichiro
    Yasojima, Hiroyuki
    Tomioka, Nobumoto
    BREAST CANCER, 2016, 23 (06) : 830 - 843
  • [37] An efficacy and safety trial of preoperative chemo-endocrine therapy in luminal B (HER2-negative) breast cancer: A prospective multi-institutional study
    Matsunuma, R.
    Ogura, H.
    Ide, Y.
    Hosokawa, Y.
    Yoshida, Y. Taki M.
    Tokunaga, Y.
    Koizumi, K.
    Sato, T.
    Hozumi, Y.
    Mori, H.
    Miyamoto, Y.
    Watanabe, T.
    Shiiya, N.
    CANCER RESEARCH, 2013, 73
  • [38] HER2-negative metastatic breast cancer patients receiving first-line docetaxel: Survival data and prognostic factors
    Deblock, M.
    Esterni, B.
    Tarpin, C.
    Charaffe-Jauffret, E.
    Extra, J. M.
    Viens, P.
    Goncalves, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [39] Neoadjuvant docetaxel with or without carboplatin plus dual HER2 blockade for HER2-positive breast cancer: a retrospective multi-center Chinese study
    Lv, Minhao
    Guo, Huihui
    Wang, Chao
    Tian, Peiqi
    Ma, Youzhao
    Chen, Xiuchun
    Luo, Suxia
    GLAND SURGERY, 2020, 9 (06) : 2079 - 2090
  • [40] Clinical Validation of BCT Scores With Prognostic Factors in Hormone Receptor-positive, HER2-negative Early Breast Cancer
    Lee, Jeeyeon
    Kim, Won Hwa
    Jung, Jin Hyang
    Kim, Wan Wook
    Park, Chan Sub
    Lee, Ryu Kyung
    Park, Jee Young
    Chae, Yee Soo
    Lee, Soo Jung
    Kim, Hye Jung
    Park, Ji-Young
    Park, Ho Yong
    IN VIVO, 2019, 33 (06): : 2133 - 2139
12345